#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16902	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2342	718.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1542	1542	C	965	C	898	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30414	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3700	820.3	0	.	n	.	0	T695C	SNP	695	695	T	1034	1034	C	947	C	881	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30414	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3700	820.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1676	1676	A	1002	A	914	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30414	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3700	820.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2310	2310	C	933	C,T	870,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30414	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3700	820.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2936	2936	T	985	T	920	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30414	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3700	820.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2384	2384	A	979	A	930	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2124	folP	852	852	100.0	folP.l15.c4.ctg.1	1532	137.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1004	1006	AGC	207;208;207	A;G;C,A	191;191;190,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5648	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3470	162.4	1	SNP	p	S91F	0	.	.	271	273	TCC	574	576	TCC	196;197;198	T;C,T,G;C	185;186,1,1;190	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5648	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3470	162.4	1	SNP	p	D95G	0	.	.	283	285	GAC	586	588	GAC	204;203;202	G;A,G;C	195;191,1;194	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5648	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3470	162.4	1	SNP	p	D95N	0	.	.	283	285	GAC	586	588	GAC	204;203;202	G;A,G;C	195;191,1;194	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1744	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1268	136.7	1	SNP	p	G45D	1	.	.	133	135	GAC	425	427	GAC	213;213;212	G;A,G;C	202;198,1;201	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	868	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1145	75.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5772	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2964	194.1	1	SNP	p	D86N	0	.	.	256	258	GAC	579	581	GAC	207;210;209	G;A;C	193;190;192	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5772	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2964	194.1	1	SNP	p	S87I	0	.	.	259	261	AGT	582	584	AGT	209;209;211	A;G;T	194;192;194	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5772	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2964	194.1	1	SNP	p	S87R	0	.	.	259	261	AGT	582	584	AGT	209;209;211	A;G;T	194;192;194	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5772	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2964	194.1	1	SNP	p	S87W	0	.	.	259	261	AGT	582	584	AGT	209;209;211	A;G;T	194;192;194	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5772	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2964	194.1	1	SNP	p	S88P	0	.	.	262	264	TCC	585	587	TCC	209;209;208	T,A;C;C	194,1;190;188	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4466	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2578	172.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1532	1534	GGC	219;219;221	G;G;C	203;201;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1387	1389	GCA	223;220;217	G;C;A	196;199;199	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1390	1392	ATC	218;220;223	A;T;C	198;198;203	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1402	1404	GTG	222;220;220	G;T,C;G	206;203,1;206	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1402	1404	GTG	222;220;220	G;T,C;G	206;203,1;206	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1906	1908	ACC	238;238;240	A;C;C	225;227;230	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1960	1962	GCG	230;229;225	G;C;G	193;171;179	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1960	1962	GCG	230;229;225	G;C;G	193;171;179	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2083	2085	GGC	205;204;204	G;G;C	188;187;187	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2092	2094	GGC	201;196;193	G;G;C	180;177;170	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4180	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2533	164.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2110	2112	CCG	169;171;171	C,G;C;GCCC,GGCCCC	121,2;125;117,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6286	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3218	194.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1700	1702	CTG	226;227;224	C;T;G	208;207;206	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2600	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1780	145.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	578	578	C	163	C	149	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	623	625	GGA	262;262;263	G;G;A	242;241;242	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	740	742	GCT	253;257;255	G;C;T	235;235;234	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	746	748	AGC	254;249;248	A;G;C,A	233;228;227,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	838	839	CG	255;255	C;G	236;234	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	841	843	CAG	243;245;246	C;A;G,A	224;224;225,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	845	847	AAA	254;257;257	A;A;A	237;239;238	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	N134S	NONSYN	400	402	AAT	881	883	AGT	266;270;270	A,G;G,A;T	244,1;248,1;245	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	908	910	GAA	274;274;280	G,A;A;A	256,1;257;261	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	932	934	GCA	282;284;284	G;C,T;A	263;265,1;259	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1040	1042	CAA	266;266;267	C;A;A	249;250;248	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1046	1048	AGC	268;268;269	A;G;C	250;250;251	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	M209I	NONSYN	625	627	ATG	1106	1108	ATC	260;257;259	A;T;C	236;234;233	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	0	.	p	.	0	E210fs	FSHIFT	628	628	G	1109	1109	G	260	G	239	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	1	SNP	p	G120K	1	.	.	358	360	AAG	838	840	CGG	255;255;247	C;G;G	236;234;227	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	1	SNP	p	D121N	0	.	.	361	363	GAC	841	844	CGC	243;246;250	C;G,A;C	224;225,1;233	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3214	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1662	192.0	1	SNP	p	A121D	1	.	.	361	363	GAC	841	844	CGC	243;246;250	C;G,A;C	224;225,1;233	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11972	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4889	244.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1999	2001	AAT	260;261;260	A;A;T	245;244;246	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1338	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1083	122.7	1	SNP	p	V57M	1	.	.	169	171	ATG	530	532	ATG	282;285;285	A;T;G	266;269;267	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
